Detection of ARV-Resistant Mutants in HIV-1-Infected Individuals in a Context of Systematic Switching to an Association Based on Dolutegravir in Abidjan, Côte d’Ivoire
- 1 Molecular Biology Platform, Institut Pasteur, Abidjan, Côte d’Ivoire
- 2 Molecular Biology Platform, Institut Pasteur, Abidjan, Côte d’Ivoire
- 3 Laboratory of the Regional Blood Transfusion Center, Yamoussoukro, Côte d’Ivoire
- 4 Department of Infectious and Tropical Diseases, University Hospital Treichville, Abidjan, Côte d’Ivoire
- 5 Molecular Biology Platform, Institut Pasteur, Abidjan, Côte d’Ivoire
- 6 Molecular Biology Platform, Institut Pasteur, Abidjan, Côte d’Ivoire
- 7 Laboratory of the Regional Blood Transfusion Center, San-Pédro, Côte d’Ivoire
- 8 Department of Epidemic Virus, Institut Pasteur, Abidjan, Côte d’Ivoire
- 9 Department of Epidemic Virus, Institut Pasteur, Abidjan, Côte d’Ivoire
- 10 Molecular Biology Platform, Institut Pasteur, Abidjan, Côte d’Ivoire
- 11 Department of Parasitology Mycology, Institut Pasteur, Abidjan, Côte d’Ivoire
- 12 Department of Bacteriology-Virology, Institut Pasteur, Abidjan, Côte d’Ivoire
Abstract
The emergence of antiretroviral resistance mutations represents a major threat to the achievement of national and global goals for the elimination of HIV-1 infection. The global strategy in 2019 in C ô te d'Ivoire is a new national policy for the management of people living with HIV with the administration of dolutegravir (DTG)-based fixed-dose combination. The aim of our study was to evaluate HIV-1 resistance to antiretrovirals (ARVs) in infected adult subjects in C ô te d’Ivoire in the context of a systematic switch to a DTG-based combination. Between February 2022 and October 2023, a cross-sectional survey with random sampling was conducted in 06 services caring for people living with HIV. A total of 139 participants were included in the study. Adults with a viral load ≥ 1000 copies/mL were tested for HIV-1 ARV resistance mutations. Molecular analyses were performed using protocol of ANRS-MIE (National Agency for Research on AIDS and emerging infectious diseases). The interpretation is performed by HIVGRAD ( https://www.hiv-grade.de/cms/grade/ ). The frequencies of HIV-1 resistance to non-nucleotide reverse transcriptase inhibitors (NNRTIs), nucleotide reverse transcriptase inhibitors (NRTIs), integrase inhibitors (IINTs) and protease inhibitors (PIs) were 82%, 73%, 19% and 11% respectively. The main mutations observed in the different classes were K103N (45%), M184V (64%), E157Q (19%) and L10V/M46I/A71V/I54V (6%) respectively. This study reveals the emergence of resistance to DTG-based fixed-dose combinations, favored by high rates of resistance to NRTIs and NNRTIs. This finding underlines the need for enhanced viral load monitoring and HIV-1 genotyping tests to guide the choice of NRTIs for combination therapy. In addition, monitoring for mutations to second-generation NRTIs is essential, given the scale-up of DTG-based regimens currently underway in C ô te d’Ivoire.
- ONUSIDA (2023) Fiche d’information. Dernières statistiques sur l’état de l’épidémie de sida. https://www.unaids.org/fr/resources/fact-sheet
- WHO (2021) HIV Drug Resistance Report. https://www.who.int/publications-detail-redirect/9789240038608
- WHO (2016) World Health Organization: Consolidated guidelines. Genève. https://scholar.google.com/scholar_lookup?title=Consolidated+guidelines+on+the+use+of+antiretroviral+drugs+for+treating+and+preventing+HIV+infection.+Recommendations+for+a+public+health+approach+-+Second+edition.+2nd+ed&publication_year=2018&
- Dechi, J.J.R., Toni, T.D., Cisse-Camara, M., Philippe, N.J.L., Ake, A.J.A., Siransy, K.L., et al . (2022) Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochemistry and Molecular Biology , 7, 70-74.
- Kouamou, V., Manasa, J., Katzenstein, D., McGregor, A.M., Ndhlovu, C.E. and Makadzange, A.T. (2019) Drug Resistance and Optimizing Dolutegravir Regimens for Adolescents and Young Adults Failing Antiretroviral Therapy. AIDS , 33, 1729-1737. https://doi.org/10.1097/QAD.0000000000002284
- Bivigou-Mboumba, B., Iroungou, B.A., Moussavou-Boundzanga, P., Mangouka, L.G., Akombi, F.L., Bouassa-Bouassa, A., Francois-Souquière, S. and Nzenze, J.R. (2022) HIV Genetic Diversity, Virological Failure, and Drug Resistance in Libreville, Capital of Gabon, before a Total Dolutegravir-Based Regimen Transition. World Journal of AIDS , 12, 156-168. https://doi.org/10.4236/wja.2022.123012
- Appah, A., Beelen, C.J., Kirkby, D., Dong, W., Shahid, A., Foley, B., Mensah, M., Ganu, V., Puplampu, P., Amoah, L.E., et al . (2023) Molecular Epidemiology of HIV-1 in Ghana: Subtype Distribution, Drug Resistance and Coreceptor Usage. Viruses , 15, 128. https://doi.org/10.3390/v15010128
- Clutter, D.S., Jordan, M.R., Bertagnolio, S. and Shafer, R.W. (2016) HIV-1 Drug Resistance and Resistance Testing. Infection , Genetics and Evolution , 46, 292-307. https://doi.org/10.1016/j.meegid.2016.08.031
- Fily, F., Ayikobua, E., Ssemwanga, D., Nicholas, S., Kaleebu, P., Delaugerre, C., Pasquier, E., Amoros Quiles, I., Balkan, S. and Schramm, B. (2018) HIV-1 Drug Resistance Testing at Second-Line Regimen Failure in Arua, Uganda: Avoiding Unnecessary Switch to an Empiric Third-Line. Tropical Medicine & International Health , 23, 1075-1083. https://doi.org/10.1111/tmi.13131
- Salou, M., Butel, C., Comlan, A.S., Konou, A.A., Tegueni, K., Ehlan, A., Lack, F., Dossim, S., Ayouba, A., Delaporte, E., Dagnra, A.Y. and Peeters, M. (2020) Challenges of Scale-Up to Dolutegravir-Based Regimens in Sub-Saharan Africa. AIDS , 34, 783-787. https://doi.org/10.1097/QAD.0000000000002470